查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552627

抗精神病藥物市場規模、佔有率、趨勢分析報告：按疾病、藥物、治療藥物類別、分銷管道、地區、細分市場預測，2024-2030

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

抗精神病藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球抗精神病藥物市場規模將達到249.7億美元，2024年至2030年複合年成長率為6.1%。

不斷開發更好的下一代產品以克服現有產品的副作用和不良反應，正在創造對新產品的需求。預計這將推動市場。

抗精神病藥物的快速成長是由於精神病和其他精神障礙的盛行率上升。各國政府正致力於提高人們對心理健康和精神疾病的意識提升，預計將進一步推動抗精神病藥物的需求。政府機構正在與大公司合作實施社會計劃，以消除社會上與精神障礙相關的恥辱。

抗精神病藥物的副作用，如失眠、口乾、嗜睡和視力模糊，預計會降低患者的接受程度，進而影響生長。此外，潛在的依賴性、習慣形成和成癮也影響了這些藥物的採用。

Zyprexa於 2011 年 10 月失去專利保護，Seroquel和Risperdal於 2012 年失去專利保護，阻礙了這些藥物的市場成長。學名藥的進入也減緩了現有品牌的成長。

抗精神病藥物市場報告亮點

  • 2023年，思覺失調症將佔最大的市場收益佔有率，達到39.2%。思覺失調症是一種嚴重的精神疾病，影響著世界各地的許多人。
  • Aripiprazole在 2023 年佔最大的市場銷售佔有率。由於採用第三代產品，該細分市場的銷售額將會增加。此外，預計產品核可在預測期內將出現最高成長。
  • 預計 Brexpiprmaze 在預測期內的複合年成長率將達到 9.8%，是最快的。
  • 2023年，第二代治療類別佔最大的市場收益佔有率，達62.9%。該細分市場的成長歸因於市場上存在許多第二代藥物，例如 Hafila、Invega、 Seroquel XR 和Zyprexa。
  • 零售藥局領域主導市場，並在 2023 年佔據最大佔有率。零售藥局對於患者來說很方便，通常是需要處方藥的患者的第一個接觸點。
  • 北美市場佔據主導地位，2023 年收益佔有率為 37.67%。促成該地區市場主導地位的重要因素包括該地區精神障礙的嚴重流行以及著名生物製藥公司的市場影響。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章抗精神病藥物市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗精神病藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章抗精神病藥物市場：依疾病分類的估計與趨勢分析

  • 細分儀表板
  • 抗精神病藥物市場：2023年及2030年疾病變化分析
  • 思覺失調症
  • 躁鬱症
  • 單相情感障礙
  • 失智
  • 其他

第5章抗精神病藥物市場：按藥物估計和趨勢分析

  • 細分儀表板
  • 抗精神病藥物市場：2023年及2030年藥物波動分析
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • 帕潘立酮棕櫚酸酯
  • 其他

第6章 抗精神病藥物市場：依治療藥物類別估計與趨勢分析

  • 細分儀表板
  • 抗精神病藥物市場：2023年和2030年治療藥物類別的波動分析
  • 第一代
  • 第二代
  • 第三代

第7章抗精神病藥物市場：按分銷管道的估計和趨勢分析

  • 細分儀表板
  • 抗精神病藥物市場：2023 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章抗精神病藥物市場：區域估計和趨勢分析

  • 2023 年和 2030 年抗精神病藥物市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • H.Lundbeck A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Global Services, LLC
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Sumitomo Pharma
    • Alkermes
    • Bristol-Myers Squibb Company
簡介目錄
Product Code: GVR-1-68038-408-6

Antipsychotic Drugs Market Growth & Trends:

The global antipsychotic drugs market size is expected to reach USD 24.97 billion by 2030, growing at CAGR of 6.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The continuous development of better next-generation products to overcome adverse effects and unwanted reactions of existing products is creating demand for newer products. This factor is anticipated to propel the market.

Rapid growth of antipsychotics can be attributed to the rising prevalence of psychosis and other mental disorders. Governments are focused on creating awareness regarding mental health and psychological illnesses, which is further anticipated to drive the demand for antipsychotics. Government bodies in collaboration with major players conduct social programs to break the stigma related to psychotic disorders that exists in the society.

Adverse effects of antipsychotics, such as insomnia, dry mouth, drowsiness, and blurred vision, are expected to affect the growth by decreasing the level of acceptance in patients. In addition, the possibility of dependency, habit formation, or addiction is affecting the adoption of these drugs.

Established brands such as, Zyprexa lost patent protection in October 2011, followed by Seroquel and Risperdal in 2012, which hampers the market growth for these drugs. Also, the entry of generic versions of these products slowed the growth of the already existing brands.

Antipsychotic Drugs Market Report Highlights:

  • Schizophrenia accounted for the largest market revenue share of 39.2% in 2023. Schizophrenia is a serious mental illness that impacts a significant amount of individuals worldwide.
  • Aripiprazole accounted for the largest market revenue share in 2023. The sales of this segment increase with the adoption of third-generation products. Furthermore, it is anticipated that product approvals are expected to experience the most significant growth during the projected period.
  • Brexpiprazole is expected to register the fastest CAGR of 9.8% during the forecast period.
  • The second generation therapeutic class accounted for the largest market revenue share of 62.9% in 2023. The growth of this segment can be attributed to the presence of a number of second-generation medications available in the market, such as HAFYERA, INVEGA, SEROQUEL, XR, ZYPREXA, and others.
  • The retail pharmacies segment dominated the market and accounted for the largest share in 2023. Retail pharmacies are easily available to patients, and they often act as the initial point of contact for individuals in need of prescription medications.
  • North America dominated the market with revenue share of 37.67% in 2023. Some of the critical factors attributable to the region's market dominance include the strong prevalence of psychiatric illnesses in the region and the market presence of prominent biopharmaceutical companies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Antipsychotic Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antipsychotic Drugs Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Schizophrenia
    • 4.3.1. Schizophrenia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Bipolar Disorder
    • 4.4.1. Bipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Unipolar Disorder
    • 4.5.1. Unipolar Disorder Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dementia
    • 4.6.1. Dementia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antipsychotic Drugs Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Risperidone
    • 5.3.1. Risperidone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Quetiapine
    • 5.4.1. Quetiapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Olanzapine
    • 5.5.1. Olanzapine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Aripiprazole
    • 5.6.1. Aripiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Brexpiprazole
    • 5.7.1. Brexpiprazole Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Paliperidone Palmitate
    • 5.8.1. Paliperidone Palmitate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. First Generation
    • 6.3.1. First Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Second Generation
    • 6.4.1. Second Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Third Generation
    • 6.5.1. Third Generation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Retail Pharmacies
    • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Online Pharmacies
    • 7.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Antipsychotic Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Canada Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. U.K.
      • 8.3.2.1. U.K. Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Germany Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. France Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Italy Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Spain Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Norway Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. China
      • 8.4.2.1. China Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Japan Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. India Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Australia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Saudi Arabia
      • 8.6.2.1. Saudi Arabia Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. UAE
      • 8.6.3.1. UAE Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. South Africa
      • 8.6.4.1. South Africa Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Antipsychotic Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
    • 9.4.1. H.Lundbeck A/S
      • 9.4.1.1. Participant's Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Recent Developments/ Strategic Initiatives
    • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
      • 9.4.2.1. Participant's Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Recent Developments/ Strategic Initiatives
    • 9.4.3. Janssen Global Services, LLC
      • 9.4.3.1. Participant's Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Recent Developments/ Strategic Initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Participant's Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Recent Developments/ Strategic Initiatives
    • 9.4.5. AbbVie, Inc.
      • 9.4.5.1. Participant's Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Recent Developments/ Strategic Initiatives
    • 9.4.6. Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1. Participant's Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Recent Developments/ Strategic Initiatives
    • 9.4.7. Dr. Reddy's Laboratories Ltd.
      • 9.4.7.1. Participant's Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Recent Developments/ Strategic Initiatives
    • 9.4.8. Sumitomo Pharma
      • 9.4.8.1. Participant's Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Recent Developments/ Strategic Initiatives
    • 9.4.9. Alkermes
      • 9.4.9.1. Participant's Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Recent Developments/ Strategic Initiatives
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Participant's Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Recent Developments/ Strategic Initiatives